national stem-cell therapy logo

FUJIFILM Cellular Dynamics Announces License Agreement with Novo Nordisk for the Development of iPSC-Derived Cell Therapies

Fujifilm logo

MADISON, Wis., Jan. 05, 2023 (GLOBE NEWSWIRE) — FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC), announced today that it has entered an agreement to grant global healthcare company Novo Nordisk A/S a non-exclusive right to use FUJIFILM Cellular Dynamics’ iPSC platform for the development and […]

Century Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Century Therapeutics logo

PHILADELPHIA, Jan. 04, 2023 (GLOBE NEWSWIRE) — Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Lalo Flores, Ph.D., Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 9:45 AM PT. A live webcast of […]

Aspen Neuroscience Inks $40 Million Debt Deal with Silicon Valley Bank

Aspen Neuroscience Logo

SAN DIEGO, Dec. 21, 2022 /PRNewswire/ — Aspen Neuroscience, Inc., a private biotechnology company developing autologous cell therapies including the first iPSC-derived autologous neuron replacement treatment for Parkinson’s disease (PD), has signed a $40 million credit facility with Silicon Valley Bank (SVB). Deal terms were not disclosed. “We are pleased to work with Silicon Valley Bank. As a leader […]

Fate Therapeutics Features Multiple Novel Approaches to Eliminate Conditioning Chemotherapy for Off-the-shelf, iPSC-derived Cell Therapies at 2022 ASH Annual Meeting

Fate Therapeutics logo

SAN DIEGO, Dec. 13, 2022 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, presented preclinical data of several novel strategies designed to enable administration of off-the-shelf cell-based cancer immunotherapies without conditioning chemotherapy at the 64th American Society of Hematology […]

GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022

GT Biopharma Logo

BRISBANE, CALIFORNIA, Dec. 12, 2022 (GLOBE NEWSWIRE) — GT Biopharma, Inc. (NASDAQ: GTBP) today announced the presentation of new preclinical data at the American Society of Hematology’s 64th Annual Meeting (ASH 2022). The presentation highlights the potential of a novel dual antigen targeting approach for the treatment of acute myeloid leukemia (AML) by combining GT […]

2022 Ogawa-Yamanaka Stem Cell Prize Awarded to Juan Carlos Izpisua Belmonte – Award Ceremony

Ogawa-Yamanaka Stem Cell Prize 2022

On November 17, 2022, Gladstone Institutes honored the 2022 Ogawa-Yamanaka Stem Cell Prize winner, Juan Carlos Izpisua Belmonte. Izpisua Belmonte is a celebrated scientist known for his regenerative medicine and aging research, as well as his work leading to improved methods of generating induced pluripotent stem cells (iPSCs). In a translational leap, his group was […]

I Peace partners with the California Institute for Regenerative Medicine [CIRM]

I Peace logo

PALO ALTO, Calif., Nov. 1, 2022 /PRNewswire/ — I Peace, Inc. (https://www.ipeace.com) announced that the company has agreed to join the California Institute for Regenerative Medicine’s (CIRM) Industry Resource Partner Program to pave way for the provision of Good Manufacturing Practice (GMP) iPSCs for various research programs funded by CIRM. I Peace has been providing GMP Induced Pluripotent […]

BREAKTHROUGH TECHNOLOGY FOR IPS-DERIVED CELL THERAPIES TURNED INTO GMP PLATFORM BY TREEFROG THERAPEUTICS & INVETECH

TreeFrog's C-Stem technology

BORDEAUX, France, Oct. 11, 2022 /PRNewswire/ — TreeFrog Therapeutics, a biotechnology company developing stem cell-derived therapies in regenerative medicine and immuno-oncology based on the biomimetic C-Stem™ technology platform, and Invetech, a global leader in the development and production of automated manufacturing solutions for cell and advanced therapies, today announced the delivery of a GMP-grade cell encapsulation device using the C-Stem™ technology. […]

Searching for a Spina Bifida Cure Part 1 – The Promise of Stem Cells

Searching for a Spina Bifida Cure Part 1 - The Promise of Stem Cells

The first ever in utero stem cell treatment for spina bifida is the culmination of decades of work from UC Davis surgeon-scientist Diana Farmer. This novel fetal surgery at UC Davis Children’s Hospital could change the life of a developing baby with spina bifida, who otherwise could be born paralyzed from the waist down. In […]

RoslinCT and Lykan Bioscience Combine to Create Leading Advanced Cell Therapy CDMO

RoslinCT and Lykan logos

EDINBURGH, UK AND HOPKINTON, MA, 4 August 2022 – RoslinCT, a cell and gene therapy Contract Development and Manufacturing Organisation (‘CDMO’) developing life-changing therapies in Edinburgh’s BioQuarter, and Lykan Bioscience (‘Lykan’), an innovative CDMO focused on cell-based therapies, today announce that they have entered into a business combination agreement to form a global leading innovative […]